Attention-deficit hyperactivity disorder (ADHD) af fects one in 20 Canadian children, and is associat ed with unfavourable academic and employment records, high rates of injury and substance abuse, poor interpersonal relationships, poor mental health outcomes and poor quality of life. Medications have been shown to be efficacious in treating ADHD symptoms in controlled trials, and are associated with better social and health outcomes in observa tional studies. Extended-release (XR) medications for ADHD are preferred over short-acting immedi ate-release medications by many families and their treating physicians. The XR preparations are often unaffordable for affected families who are dispro portionally among the lower socioeconomic strata. The objective of the present statement was to criti cally appraise the evidence for the relative effec tiveness of XR versus immediate-release medica tions, and to make recommendations for their ap propriate use in the treatment of ADHD. When medication is indicated, XR preparations should be considered as first-line therapy for ADHD because they are more effective and less likely to be divert ed. Future research and cost-benefit analyses should consider both efficacy and effectiveness, and the diversion and misuse potentials of these medications. Industry, insurance companies and government must work together to make these medications accessible to all children and youth with ADHD.
Extended-release (XR) medications are preferred over short-acting medications by many families affected with attention-deficit hyperactivity disorder (ADHD) and by prescribing physicians with expertise in treating AD HD [1] - [4] . The XR preparations, however, are expensive and often unaffordable for affected families because ADHD is disproportionately diagnosed among children from disadvantaged populations [5] within advantaged countries [6] . Not all Canadian public and private med ication insurance plans cover XR medications for AD HD. The objective of the present statement was to ex amine the evidence for the relative effectiveness of XR versus immediate-release (IR) medications, and to make recommendations for their appropriate use in the treatment of ADHD.
Methods
XR medications for the treatment of ADHD came to market in the year 2000 or thereafter. PubMed and the Cochrane Central Register of Controlled Trials were searched for publications from 1998 to 2008 using the following search terms: ADHD, attention deficit disor der, compliance, OROS methylphenidate (MPH), ex tended-release, immediate-release, atomoxetine, Adderall XR, mixed amphetamine salt, quality of life and effectiveness. In addition, a search was conducted for relevant systematic reviews from the Cochrane database and for relevant references from identified articles. The quality of the studies were appraised us ing the methods of Sackett et al [7] , and systematic re views were appraised using the method of Guyatt et al [8] .
Background
ADHD affects approximately one in 20 children world wide [6] , and if suboptimally treated, ADHD is charac terized by inattention, impulsivity and hyperactivity. Af fected individuals report a reduced quality of life [9] , and are at increased risk for injuries [10] , behaviour problems and difficulty in school (both academically and socially) [11] . Children diagnosed with ADHD have a higher risk of grave long-term outcomes [12] - [15] .
The best available evidence from randomized con trolled trials demonstrates that when compared with children with ADHD whose therapy does not include medication, children who are treated with medication do better academically [16] - [19] and socially [20] . Further more, because learning, behavioural and emotional is sues are frequently comorbid among children with AD HD, some who are treated with both stimulant medica tion and behavioural strategies have the best out comes with respect to social skills, parent-child rela tionships and reading achievement [21] .
Long-term observational studies comparing treated and untreated children with ADHD indicate that treat ment with stimulant medication is associated with a re duced risk of poor social outcomes, such as develop ing drug or alcohol addiction [22] [23] .
Given both the potential benefit of stimulant medication for ADHD and the potential side effects of medication, it is important to determine which properties of the vari ous available preparations for ADHD improve compli ance, minimize side effects and maximize effective ness.
Effectiveness of XR versus IR medications for ADHD
The term 'efficacy' describes how well a treatment works under tightly controlled study conditions. The term 'effectiveness' describes how well a treatment works in a natural setting in real-world conditions. A treatment may be efficacious but ineffective if the tar get population refuses to take it. Effective treatment for ADHD with short-acting IR medications requires the administration of repeated doses during the day. Ad verse effects of repeated doses of IR medication, plus the stigma associated with taking these medications at school as well as the disruption to the school routine, may contribute to a child becoming disinclined to take medication, ultimately rendering the prescribed therapy ineffective.
Although there is little debate that efficacy during school hours is similar for XR and IR preparations of stimulant medications [24] , there now exists a body of literature showing important differences in effective ness between XR and IR medications for the treatment of ADHD.
Surveys [25] [26] [27] report that nearly one-half of the pa tients prescribed IR stimulant medication admit they are not taking the medication.
Upon study completion at 14 months, the landmark Multimodal Treatment Arm study [21] demonstrated considerable symptomatic relief among children with ADHD randomly assigned to receive carefully titrated IR MPH, compared with children in the nonmedicated arm and the routine community care group. The initial Multimodal Treatment Arm cohort that received med ication was subsequently re-evaluated retrospectively and found to have more modest advantages in terms of core ADHD symptoms when observed at 24 months [28] , and virtually no advantage by 36 months [29] . The reduction in effectiveness can be explained, at least in part, by reduced compliance over time among the group initially assigned to medication [28] [29] .
It is difficult to determine exactly which characteristics of various ADHD medications affect compliance differ ently. Although adverse effects are commonly reported as reasons for discontinuing ADHD treatment, there is inadequate evidence from the published literature to determine whether the adverse effect profiles of XR medications and IR medications differ sufficiently to differentially affect compliance.
An important determinant of compliance with stimulant medication is the age of the child. Older children are more likely to discontinue treatment [27] [30] . It may be that older children are less likely to comply with IR medication because of the stigma associated with the administration of the medication by school staff.
On the other hand, while long-acting XR medications for ADHD obviate the need for the interruptions and the stigma associated with multiple daily dosing during school hours, other factors related to XR medications may deter compliance. Empirically, there are reported differences in compliance when researchers compare IR stimulants with XR stimulants for ADHD.
In a randomized, unblinded, controlled trial [2] compar ing XR MPH with IR MPH, the authors reported better adherence in the XR arm of the study, even under strict study conditions (which tend to improve compli ance in both arms).
In a comparison of prescriptions written with prescrip tions filled from a Texas Medicaid database, Sanchez et al [31] showed a significantly higher 'medication pos session ratio' for XR MPH than for IR MPH. Similarly, using a California Medicaid database, Marcus et al [32] showed that children treated with XR MPH used their prescribed medication for a 37% longer duration than those prescribed IR MPH.
Using data from the United States Integrated Health Care Information Services administrative database, Lage and Hwang [33] showed that children who were initially treated with XR stimulant medications were less likely to switch, discontinue or have gaps in their treatment, than children prescribed IR stimulant med ications.
The inattention and impulsivity among children with ADHD places them at higher risk for injuries. Using a large insurance claims database in the United States, Kemner and Lage [34] [35] showed that children with AD HD prescribed XR stimulant medication were less like ly to visit an emergency department and less likely to be hospitalized than those initially prescribed IR stimu lant medications. Moreover, if hospitalized, children prescribed XR stimulant medications stayed in hospital for a shorter period of time than children with ADHD prescribed IR stimulant medications. What makes these latter observational studies more compelling is that the authors controlled for demographic character istics, patient general health status and comorbid diag noses.
It is difficult to know whether the favourable risk for emergency department visits and hospitalizations as sociated with XR preparations is due to enhanced ef fectiveness of XR preparations (due to enhanced com pliance) or enhanced efficacy of XR preparations be cause of their prolonged therapeutic effect with a re duction in inattentive or impulsive (risk-taking) behav iours in the evening.
In summary, the best available evidence indicates that although XR medications are not necessarily more effi cacious than IR medications, they are more effective than IR medications for the treatment of ADHD. Re cently, the United Kingdom's National Institute for Clini cal Excellence published an evidence-based guideline [36] with recommendations concerning the appropriate use of pharmacotherapy for children and adults with ADHD. In this guideline, the authors concluded that when children or young people are prescribed MPH, modified-release preparations should be considered. The reasons for this included:
• improving adherence,
• reducing stigma (because the child or young per son does not need to take medication at school),
• reducing problems schools have in storing and ad ministering controlled drugs, and
• their pharmacokinetic profiles.
Misuse and diversion of XR versus IR medications for ADHD
'Diversion' of medication may be defined as the trans fer of medication from one patient for whom it is pre scribed to another patient for whom it is not prescribed. 'Misuse' refers to the use of nonprescribed medica tions or the use of prescribed medications at doses, times or in combinations other than for which they were prescribed.
Compared to those without ADHD, children with ADHD have a higher risk of substance abuse. However, chil dren with ADHD who are treated with medication have a lower risk of substance abuse than children with AD HD who are not treated [22] [23] .
A minority of treated adolescents with ADHD, however, will misuse or divert their medication. Eleven per cent of middle-class adolescents and young adults sur veyed from a large United States health maintenance organization reported that they sold their stimulant medication and that 22% misused it. The subgroup with comorbid conduct disorder was at greatest risk [37] . In Canada, a survey [38] of high school children from the Atlantic provinces revealed that 26% of ado lescents report having diverted their ADHD medica tions at one time or more. These surveys studied chil dren who were, for the most part, prescribed IR MPH.
In a three-arm, double-blind, crossover comparison [39] of XR MPH, IR MPH and placebo among recreational drug users in Toronto, Ontario, study subjects were asked for their opinion regarding which preparation would have the most potential to be misused. Respon dents subjectively reported IR MPH to have significant ly higher misuse potential than that of the XR MPH.
A recently published, well-designed Internet-based sur vey [40] regarding the nonmedical use of MPH among college students was conducted. Significantly more students reported having used IR MPH than XR MPH for 'partying' and the route of choice was intranasal.
Misuse of XR MPH in this study was reported at a much lower rate and was more likely to be used for 'studying' as opposed to 'partying'.
The coating mechanism of XR preparations for ADHD may make the active stimulant more difficult to extract and less likely to produce euphoria. If this is true, XR preparations should be less likely to be diverted or misused than IR preparations. Intranasal use of XR MPH to achieve a 'high' has been reported to be un successful in case series [41] .
A recent systematic review of the literature by Wilens et al [42] examined the diversion and misuse of ADHD medications. They concluded that IR stimulants are more likely than XR stimulants to be associated with diversion and misuse.
Recommendations
• When stimulant medications for ADHD are indicat ed, XR preparations should be considered as firstline therapy because these preparations are more effective and less likely to be diverted. XR medica tions are more likely than IR medications to be used by the children and teenagers with ADHD for whom they have been prescribed.
• Future research and cost-benefit analyses should take into consideration both efficacy and effective ness, and the diversion and misuse potential of these medications.
• Industry, private health insurance companies and government must work together to make these medications more accessible to all children with ADHD.
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